SAM #75N98026Q00819CREAGENINC

NIH Custom Synthesis of Prodrug Analogs and PNA Precursors for Preclinical Research

The National Institutes of Health (NIH), through its Office of the Director and the Hospital and Laboratory Support Division, is seeking specialized custom synthesis services to support preclinical research in cancer and HIV. - Government Buyer: - National Institutes of Health (NIH) - Office of the Director (OD) - Office of Logistics and Operations (OLAO), Office of Acquisition and Logistics Management (OALM), Hospital and Laboratory Support Division - OEMs and Vendors: - CreaGen Inc (identified as the intended contractor for synthesis services) - Products/Services Requested: - Custom synthesis, scale-up, purification, and characterization of: - Prodrug analogs (sulfanylbenzamide-derived compounds) - Cyclopentane peptide nucleic acid (PNA) precursor materials - These compounds are not commercially available and require advanced synthetic chemistry expertise - Notable Requirements: - Materials must be research-grade and suitable for preclinical evaluation in cancer and HIV therapeutic and diagnostic studies - Emphasis on the ability to produce, purify, and characterize highly specialized, non-commercial compounds - Estimated contract value not to exceed $350,000 - NAICS code: 325414 (Biological Product (except Diagnostic) Manufacturing)

Description

Background Information: The National Institute of Diabetes and Digestive and Kidney Diseases conducts and supports biomedical research to improve the understanding, prevention, and treatment of diseases affecting human health.  

  Within the Laboratory of Bioorganic Chemistry, the Synthetic Bioactive Molecules Section conducts research focused on the discovery and development of novel therapeutic compounds for the treatment and prevention of cancer and HIV infection. Ongoing studies have identified several promising sulfanylbenzamide-derived compounds and cyclopentane peptide nucleic acid precursor materials with potential applications as anti-cancer therapeutics, HIV prevention and treatment agents, and diagnostic technologies.  

  To support these research efforts, the Synthetic Bioactive Molecules Section requires synthesis scale-up, custom synthesis, purification, and characterization of optimized lead compounds and specialized precursor materials. These materials are not commercially available and require specialized synthetic expertise and production capabilities to generate quantities sufficient for continued preclinical evaluation.  

The materials produced under this requirement will be used in ongoing preclinical studies to evaluate compound activity, optimize lead candidates, and support advancement toward future clinical development.  

View original listing